Table 3. Frequency of Mutation After Exclusion of LMM and In Situ Melanomas.
| Exclusion | Rule of 2 | Rule of 3 | Rule of 4 |
|---|---|---|---|
| Exclusion of LMM and in situ melanomas | |||
| CDKN2A, CDK4, MITF, and BAP1, No. (%) | 65 (6.8) | 37 (9.8) | 27 (19.0) |
| Patients, No. | 957 | 378 | 142 |
| Exclusion of LMM | |||
| CDKN2A, CDK4, MITF, and BAP1, No. (%) | 66 (6.7) | 38 (9.8) | 27 (18.7) |
| Patients, No. | 984 | 388 | 144 |
| Exclusion of in situ melanomas | |||
| CDKN2A, CDK4, MITF, and BAP1, No. (%) | 65 (6.5) | 37 (9.3) | 27 (18.2) |
| Patients, No. | 1005 | 398 | 148 |
Abbreviations: BAP1, breast cancer 1 (BRCA1) associated protein 1; CDKN2A, cyclin-dependent kinase inhibitor 2A; CDK4, cyclin-dependent kinase inhibitor 4; LMM, lentigo maligna melanoma; MITF, microphthalmia-associated transcription factor.